These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15637958)

  • 21. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
    Tobias JS
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
    Vergote I; Abram P
    Ann Oncol; 2006 Feb; 17(2):200-4. PubMed ID: 16251200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
    Baum M
    Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal breast cancer agents: implications for the primary care provider.
    Lyon DE; Roux G; Voll S
    J Am Acad Nurse Pract; 2006 Nov; 18(11):518-23. PubMed ID: 17064329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
    Hannaford M
    Nurse Pract; 1997 Mar; 22(3):195-6, 201-2. PubMed ID: 9078523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM
    Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fulvestrant in postmenopausal women with advanced breast cancer.
    Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
    Dodwell D; Wardley A; Johnston S
    Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
    Telford C; Jones N; Livings C; Batson S
    Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
    Arora A; Potter JF
    J Am Geriatr Soc; 2004 Apr; 52(4):611-6. PubMed ID: 15066080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advancement in endocrine therapy for breast cancer].
    Yang MT; Lian ZQ
    Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
    Winters L; Habin K; Gallagher J
    Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.